We have a variety of partnerships in this country, with health care professionals; with provincial and territorial governments; with our partners such as the Canadian Institute for Health Information and the health technology body CADAS; and with international regulatory agencies as well, such as the USFDA, the EMEA, the Australian Therapeutic Goods Administration, and others. We have regularly established contacts with all these partners at a variety of levels and in a variety of fora.
The scientists, for example, go to the ICH, as was mentioned, for the harmonizing of standards. I go to Heads of Medicines Agencies meetings, where we talk about top-of-mind issues at the level of heads of agencies. I met with Andy von Eschenbach, my counterpart from the U.S., as well as the EMEA and the U.K. and 14 other countries in early December to make sure that we're all going in the right direction on whatever issue we need to work on together.
As we've said, the science across this world is the same science, and we're all facing the same problems in terms of keeping up with evolving science and technology and being able to adopt standards so that we can all do our regulatory work in a smart way. And then we retain our right, as of course each country does, in terms of the regulatory decisions we need to make based on our history, our context, our tolerance for risk.